Pay in 4 interest-free payments of $6.20 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
providers can prescribe to pharmacies where patients may apply manufacturer savings programs if available
June 2024: Structure Therapeutics reported positive Phase IIa obesity data for GSBR-1290, an oral non-peptide small-molecule GLP-1 receptor agonist, achieving 6.2% placebo-adjusted mean weight loss at 12 weeks
[27] Reduced Fat Storage : By enhancing fat oxidation and inhibiting fat storage pathways, GlucoVantage helps direct calories toward energy production rather than fat storage
Retatrutide's approximately 6-day half-life is slightly longer than tirzepatide's roughly 5 days, producing a flatter natural weekly curve
You will be automatically enrolled into our billing/refill program based on your plan
